<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">sibmed</journal-id><journal-title-group><journal-title xml:lang="ru">Сибирский научный медицинский журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Сибирский научный медицинский журнал</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2410-2512</issn><issn pub-type="epub">2410-2520</issn><publisher><publisher-name>ИЦиГ СО РАН</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15372/SSMJ20190108</article-id><article-id custom-type="elpub" pub-id-type="custom">sibmed-106</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКАЯ МЕДИЦИНА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL MEDICINE</subject></subj-group></article-categories><title-group><article-title>КАЧЕСТВО ЖИЗНИ ПАЦИЕНТОВ С МИЕЛОПРОЛИФЕРАТИВНЫМИ ЗАБОЛЕВАНИЯМИ (ОБЗОР ЛИТЕРАТУРЫ)</article-title><trans-title-group xml:lang="en"><trans-title>QUALITY OF LIFE IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS (REVIEW)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Давыдкин</surname><given-names>И. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Davydkin</surname><given-names>I. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Игорь Леонидович ДАВЫДКИН – д.м.н., проф., проректор по научной и инновационной работе, зав. кафедрой госпитальной терапии с курсами поликлинической терапии и трансфузиологии </p><p>443099, г. Самара, ул. Чапаевская, 89</p><p> </p></bio><bio xml:lang="en"><p>Igor Leonidovich DAVYDKIN – doctor of medical sciences, professor, vice rector for research and innovation technology, head of the chair of hospital therapy with courses of outpatient therapy and transfusiology </p><p>443099, Samara, Chapayevskaya str., 89</p></bio><email xlink:type="simple">rambleruse@rambler.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Попельнюк</surname><given-names>Н. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Popelnyuk</surname><given-names>N. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Наталья Сергеевна ПОПЕЛЬНЮК – к.м.н., ассистент кафедры госпитальной терапии с курсами поликлинической терапии и трансфузиологии </p><p>443099, г. Самара, ул. Чапаевская, 89</p></bio><bio xml:lang="en"><p>Natalya Sergeevna POPELNYUK – candidate of medical sciences, assistant of the chair of hospital therapy with courses of outpatient therapy and transfusiology </p><p>443099, Samara, Chapayevskaya str., 89</p></bio><email xlink:type="simple">rambleruse@rambler.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Наумова</surname><given-names>К. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Naumova</surname><given-names>K. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ксения Викторовна НАУМОВА – аспирант кафедры госпитальной терапии с курсами поликлинической терапии и трансфузиологии </p><p>443099, г. Самара, ул. Чапаевская, 89</p></bio><bio xml:lang="en"><p>Kseniya Viktorovna NAUMOVA – postgraduate student of the chair of hospital therapy with courses of outpatient therapy and transfusiology </p><p>443099, Samara, Chapayevskaya str., 89</p></bio><email xlink:type="simple">senechka.naumova@rambler.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мордвинова</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Mordvinova</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Елизавета Владимировна МОРДВИНОВА – ординатор кафедры госпитальной терапии с курсами поликлинической терапии и трансфузиологии </p><p>443099, г. Самара, ул. Чапаевская, 89</p></bio><bio xml:lang="en"><p>Elizaveta Vladimirovna MORDVINOVA – medical resident of the chair of hospital therapy with courses of outpatient therapy and transfusiology </p><p>443099, Samara, Chapayevskaya str., 89</p></bio><email xlink:type="simple">liza.mordvinova.94@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Степанова</surname><given-names>Т. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Stepanova</surname><given-names>T. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Татьяна Юрьевна СТЕПАНОВА – к.м.н., доцент кафедры госпитальной терапии с курсами поликлинической терапии и трансфузиологии </p><p>443099, г. Самара, ул. Чапаевская, 89</p></bio><bio xml:lang="en"><p>Tatyana Yurevna STEPANOVA – candidate of medical sciences, associate professor of the chair of hospital therapy with courses of outpatient therapy and transfusiology </p><p>443099, Samara, Chapayevskaya str., 89</p></bio><email xlink:type="simple">tatiana.stepanova-med@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кривова</surname><given-names>С. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Krivova</surname><given-names>S. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Светлана Петровна КРИВОВА – к.м.н., доцент кафедры госпитальной терапии с курсами поликлинической терапии и трансфузиологии </p><p>443099, г. Самара, ул. Чапаевская, 89</p></bio><bio xml:lang="en"><p>Svetlana Petrovna KRIVOVA – candidate of medical sciences, associate professor of the chair of hospital therapy with courses of outpatient therapy and transfusiology </p><p>443099, Samara, Chapayevskaya str., 89</p></bio><email xlink:type="simple">spkrsamara@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Рогозина</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Rogozina</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Анастасия Александровна РОГОЗИНА – студентка лечебного факультета </p><p>443099, г. Самара, ул. Чапаевская, 89</p></bio><bio xml:lang="en"><p>Anastasiya Aleksandrovna ROGOZINA – student of department of general medicine </p><p>443099, Samara, Chapayevskaya str., 89</p></bio><email xlink:type="simple">nastyarogozina2004@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кузьмина</surname><given-names>Т. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Kuzmina</surname><given-names>T. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Татьяна Павловна КУЗЬМИНА  – аспирант кафедры госпитальной терапии с курсами поликлинической терапии и трансфузиологии </p><p>443099, г. Самара, ул. Чапаевская, 89</p></bio><bio xml:lang="en"><p>Tatyana Pavlovna KUZMINA – medical resident </p><p>443099, Samara, Chapayevskaya str., 89</p></bio><email xlink:type="simple">tatyana_kuzmina_91@bk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Самарский государственный медицинский университет Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Samara State Medical University of Minzdrav of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>01</day><month>03</month><year>2019</year></pub-date><volume>39</volume><issue>1</issue><fpage>58</fpage><lpage>65</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Давыдкин И.Л., Попельнюк Н.С., Наумова К.В., Мордвинова Е.В., Степанова Т.Ю., Кривова С.П., Рогозина А.А., Кузьмина Т.П., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Давыдкин И.Л., Попельнюк Н.С., Наумова К.В., Мордвинова Е.В., Степанова Т.Ю., Кривова С.П., Рогозина А.А., Кузьмина Т.П.</copyright-holder><copyright-holder xml:lang="en">Davydkin I.L., Popelnyuk N.S., Naumova K.V., Mordvinova E.V., Stepanova T.Y., Krivova S.P., Rogozina A.A., Kuzmina T.P.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://sibmed.elpub.ru/jour/article/view/106">https://sibmed.elpub.ru/jour/article/view/106</self-uri><abstract/><trans-abstract xml:lang="en"/><kwd-group xml:lang="ru"><kwd>миелопролиферативное заболевание</kwd><kwd>хронический миелолейкоз</kwd><kwd>истинная полицитемия</kwd><kwd>качество жизни</kwd></kwd-group><kwd-group xml:lang="en"><kwd>myeloproliferative disease</kwd><kwd>chronic myeloid leukemia</kwd><kwd>polycythemia vera</kwd><kwd>quality of life</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Абдулкадыров К.М., Шуваев В.А., Мартынкевич И.С. Что нам известно об истинной полицитемии (обзор литературы и собственные данные) // Онкогематология. 2015. 10. (3). 28–42.</mixed-citation><mixed-citation xml:lang="en">Abdulkadyrov K.M., SHuvaev V.A., Martynkevich I.S. What do we know about polycythemia vera (review and own data). Onkogematologiya = Oncohematology. 2015. 10. (3). 28-42. [In Russian].</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Власова С.П., Ильченко М.Ю., Казакова Е.Б., Калакутский Л.И., Комарова М.В., Лебедев П.А., Лебедева Е.П., Максимова Л.Н., Соболева Е.В. Дисфункция эндотелия и артериальная гипертензия / ред. П.А. Лебедев. Самара: Офорт, 2010. 192 с.</mixed-citation><mixed-citation xml:lang="en">Abelsson J., Andréasson B., Samuelsson J., Hultcrantz M., Ejerblad E., Johansson B., Emanuel R., Mesa R., Johansson P. Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms // Leuk. Lymphoma. 2013. 54. (10). 2226–2230.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Волкова М.А. Клиническая онкогематология. М.: Медицина, 2007. 1144 с.</mixed-citation><mixed-citation xml:lang="en">Anderson K.R., Chambers C.R., Lam N., Yau P.S., Cusano F., Savoie M.L., Sheikh N.Medication adherence among adults prescribed imatinib, dasatinib, or nilotinib for the treatment of chronic myeloid leukemia // J. Oncol. Pharm. Pract. 2015. 21. (1). 19–25.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Воробьев А.И., Аль-Ради Л.С., Андреева Н.Е. Рациональная фармакотерапия заболеваний системы крови. М.: Литтерра, 2009. 688 с.</mixed-citation><mixed-citation xml:lang="en">Arber D.A., Orazi A., Hasserjian R., Thiele J., Borowitz M.J., Le Beau M.M., Bloomfield C.D., Cazzola M., Vardiman J.W. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia // Blood. 2016. 127. (20). 2391-2405.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Гороховская Г.Н., Хейло Т.С., Мартынов А.И. Микроциркуляция у больных артериальной гипертензией при истинной полицитемии // Междунар. журн. по иммунореабилитации. 2001. 3. (l). 48–49.</mixed-citation><mixed-citation xml:lang="en">Ault P., Kantarjian H., O’Brien S., Faderl S., Beran M., Rios M.B., Koller C., Giles F., Keating M., Talpaz M., Cortes J. Pregnancy among patients with chronic myeloid leukemia treated with imatinib // J. Clin. Oncol. 2006. 24. (7). 1204–1208.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Давыдкин И.Л., Момот А.П., Зозуля Н.И., Ройтман Е.В. Основы клинической гемостазиологии и гемореологии. Самара: Офорт, 2017. 484 с.</mixed-citation><mixed-citation xml:lang="en">Baccarani M., Deininger M.W., Rosti G., Hochhaus A., Soverini S., ApperleyJ.F., Cervantes F., Clark R.C., Cortes J.E., Guilhot F., Hjorth-Hansen H., Hughes T.P., Kantarjian H.P., Dong-Wook Kim, Larson R.A., Lipton J.H., François-Xavier Mahon, Martinelli G., Mayer J., Müller M.C., Niederwieser D., Pane F., Radich J.P., Rousselot P., Saglio G., Saußele S., Schiffer C., Silver R., Simonsson B., Steegmann J., Goldman J.M., Hehlmann R. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 // Blood. 2013. 122. (6). 872–884.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Демидова А.В., Волкова М.А. Истинная полицитемия. Клиническая онкогематология. М.: Медицина, 2001. 576 с.</mixed-citation><mixed-citation xml:lang="en">Barbui T., Barosi G., Birgegard G., Cervantes F., Finazzi G., Griesshammer M., Harrison C., Hasselbalch H.C., Hehlmann R., Hoffman R., Kiladjian J., Kröger N., Mesa R., McMullin M.F., Pardanani A., Passamonti F., Vannucchi A.M., Reiter A., Silver R.T., Verstovsek S., Tefferi A. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet // J. Clin. Oncol. 2011. 29. (6). 761-770.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Евсина О.В. Качество жизни в медицине – важный показатель состояния здоровья пациента (обзор литературы) // Личность в меняющемся мире: здоровье, адаптация, развитие. 2013. 1. (1). 119–133.</mixed-citation><mixed-citation xml:lang="en">Barbui T., Finazzi G., Carobbio A., Thiele J., Passamonti F., Rumi E., Ruggeri M., Rodeghiero F., Randi M.L., Bertozzi I., Gisslinger H., Buxhofer-Ausch V., Stefano V., Betti S., Rambaldi A., Vannucchi A.M., Tefferi A. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis) // Blood. 2012. 120. (26). 5128-5133.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Завьялова А.И. Артериальная гипертензия и безболевая ишемия миокарда при истинной полицитемии: автореф. дис. … канд. мед. наук. М., 2006.</mixed-citation><mixed-citation xml:lang="en">Barosi G., Mesa R., Finazzi G., Harrison C., Kiladjian J.J., Lengfelder E., McMullin M.F., Passamonti F., Vannucchi A.M., Besses C., Gisslinger H., Samuelsson J., Verstovsek S., Hoffman R., Pardanani A., Cervantes F., Tefferi A., Barbui T. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project// Blood. 2013. 121. (23). 4778-4781.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Ионова Т.И., Никитина Т.П., Ломаиа Е.Г., Кучма Г.Б., Мачюлайтене Е.Р., Усачёва Е.И., Шнейдер Т.В., Родионова А.Ю., Курбатова К.А. Показатели качества жизни, профиль симптомов и клинический эффект терапии второй линии дазатинибом у больных хроническим миелолейкозом при резистентности или непереносимости предшествующей терапии иматинибом: результаты 2-летнего мониторинга // Онкогематология. 2015. 10. (3). 18–27.</mixed-citation><mixed-citation xml:lang="en">Breccia M., Efficace F., Sica S., Abruzzese E., Cedrone M., Turri D., Gobbi M., Carella A.M., Gozzini A., Usala E., Cavazzini F., Danise P., Tiribelli M., Binotto G., Pregno P., Bocchia M., Gaidano G., Crugnola M., Bonifacio M., Avanzini P., Celesti F., Guella A., Martino B., Annunziata M, Luciano L, Stagno F, Vallisa D, Pungolino E, Iurlo A, Rambaldi A, Nardiello I, Orlandi E., Gambacorti-Passerini C., Alimena G. Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients // Leuk. Res. 2015. 39. (10). 1055–1059.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Меликян А.Л., Туркина А.Г., Ковригина А.М., Суборцева И.Н., Сударикова А.Б., Соколова М.А., Зарицкий А.Ю., Ломаиа Е.Г., Шуваев В.А., Грицаев С.В., Мартынкевич И.С., Афанасьев Б.В., Морозова Е.В., Байков В.В., Голенков А.К., Иванова В.Л., Капланов К.Д., Поспелова Т.И., Агеева Т.А., Шатохин Ю.В., Савченко В.Г.Клинические рекомендации по диагностике и терапии ph-негативных миелопролиферативных заболеваний (истинная полицитемия, эссенциальная тромбоцитемия, первичный миелофиброз) (редакция 2016) // Гематология и трансфузиология. 2017. 62. (S1). 25–60.</mixed-citation><mixed-citation xml:lang="en">Chen T.C., Chen L.C., Huang Y.B., Chang C.S. Imatinib adherence associated clinical outcomes of chronic myeloid leukaemia treatment in Taiwan // Int. J. Clin. Pharm. 2014. 36. (1). 172–181.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Мясоедова Н.А., Тхостова Э.Б., Белоусов Ю.Б. Оценка качества жизни при различных сердечно-сосудистых заболеваниях // Качеств. клин. практика. 2002. 4. (1). 53–57.</mixed-citation><mixed-citation xml:lang="en">Clark C.E., Taylor R.S., Shore A.C., Ukoumunne O.C., Campbell J.L. Association of a difference in systolic blood pressure between arms with vascular disease and mortality: a systematic review and meta-analysis // Lancet. 2012. 379. (9819). 905-916.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Рыбас А.В. Истинная полицитемия // Вестн. мол. ученых. 2016. (3). 19–25.</mixed-citation><mixed-citation xml:lang="en">Davydkin I. L., Kondurcev V. A., Stepanova T. Yu., Bobylev S. A. Fundamentals of hemostasis: monograf. Samara: Ofort, 2009. 436 p. [In Russian].</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Тюкина Ю.В., Лодыгина Т.И. Частота сосудистых осложнений при истинной полицитемии // Бюл. СГМУ. 2011. (1). 141–142.</mixed-citation><mixed-citation xml:lang="en">Demidova A.V., Volkova M.A. Polycythemia vera. Clinical oncohematology. Moscow: Meditsina, 2001. 576 p. [In Russian].</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Шихбабаева Д.И., Шуваев В.А., Мартынкевич И.С., Абдулкадыров К.М., Зотова И.И., Удальева В.Ю., Фоминых М.С., Замотина Т.Б., Полушкина Л.Б. Собственный опыт наблюдения и лечения больных истинной полицитемией // Вестн. гематологии. 2015. 11. (4). 13–20.</mixed-citation><mixed-citation xml:lang="en">Evsina O.V. Quality of life in medicine – important factor of patient health status (literature review). Lichnost' v menyayushchemsya mire: zdorov'e, adaptaciya, razvitie = Personality in changing world: health, adaptation, development. 2013. 1. (1). 119-133. [In Russian].</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Abelsson J., Andréasson B., Samuelsson J., Hultcrantz M., Ejerblad E., Johansson B., Emanuel R., Mesa R., Johansson P. Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms // Leuk. Lymphoma. 2013. 54. (10). 2226–2230.</mixed-citation><mixed-citation xml:lang="en">Finazzi, G., Barbui T. Evidence and expertise in the management of polycythemia vera and essential thrombocythemia // Leukemia. 2008. 22. (8). 1494-1502.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Anderson K.R., Chambers C.R., Lam N., Yau P.S., Cusano F., Savoie M.L., Sheikh N.Medication adherence among adults prescribed imatinib, dasatinib, or nilotinib for the treatment of chronic myeloid leukemia // J. Oncol. Pharm. Pract. 2015. 21. (1). 19–25.</mixed-citation><mixed-citation xml:lang="en">Flynn K.E., Atallah E. Quality of life and long term therapy in patients with chronic myeloid leukemia // Curr. Hematol. Malig. Rep. 2016. 11. (2). 80–85.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Arber D.A., Orazi A., Hasserjian R., Thiele J., Borowitz M.J., Le Beau M.M., Bloomfield C.D., Cazzola M., Vardiman J.W. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia // Blood. 2016. 127. (20). 2391–2405.</mixed-citation><mixed-citation xml:lang="en">Gorokhovskaya G.N., Hejlo T.S., Martynov A.I. Microcirculation in patients with arterial hypertension while they suffer from polycythemia vera. Mezhdunarodnyy zhurnal po immunoreabilitatsii = International journal of immunorehabilitation. 2001. 3. (l). 48-49. [In Russian].</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Ault P., Kantarjian H., O’Brien S., Faderl S., Beran M., Rios M.B., Koller C., Giles F., Keating M., Talpaz M., Cortes J. Pregnancy among patients with chronic myeloid leukemia treated with imatinib // J. Clin. Oncol. 2006. 24. (7). 1204–1208.</mixed-citation><mixed-citation xml:lang="en">Guerin A., Chen L., Ionescu-Ittu R., Marynchenko M., Nitulescu R., Hiscock R., Keir C., Wu E.Q. Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase // Curr. Med. Res. Opin. 2014. 30. (11). 2317–2328.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Baccarani M., Deininger M.W., Rosti G., Hochhaus A., Soverini S., Apperley J.F., Cervantes F., Clark R.C., Cortes J.E., Guilhot F., Hjorth-Hansen H., Hughes T.P., Kantarjian H.P., Dong-Wook Kim, Larson R.A., Lipton J.H., François-Xavier Mahon, Martinelli G., Mayer J., Müller M.C., Niederwieser D., Pane F., Radich J.P., Rousselot P., Saglio G., Saußele S., Schiffer C., Silver R., Simonsson B., Steegmann J., Goldman J.M., Hehlmann R. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 // Blood. 2013. 122. (6). 872–884.</mixed-citation><mixed-citation xml:lang="en">Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance // Health Qual. Life Outcomes. 2006. 4. 79.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Barbui T., Barosi G., Birgegard G., Cervantes F., Finazzi G., Griesshammer M., Harrison C., Hassel-balch H.C., Hehlmann R., Hoffman R., Kiladjian J., Kröger N., Mesa R., McMullin M.F., Pardanani A., Passamonti F., Vannucchi A.M., Reiter A., Silver R.T., Verstovsek S., Tefferi A. Philadelphia-negative classi¬cal myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet // J. Clin. Oncol. 2011. 29. (6). 761–770.</mixed-citation><mixed-citation xml:lang="en">Hamerschlak N., de Souza C., Cornacchioni A.L., Pasquini R., Tabak D., Spector N., Steagall M. Quality of life of chronic myeloid leukemia patients in Brazil: ability to work as a key factor // Support. Care Cancer. 2014. 22. (8). 2113–2118.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Barbui T., Finazzi G., Carobbio A., Thiele J., Passamonti F., Rumi E., Ruggeri M., Rodeghiero F., Randi M.L., Bertozzi I., Gisslinger H., Buxhofer-Ausch V., Stefano V., Betti S., Rambaldi A., Vannuc¬chi A.M., Tefferi A. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis) // Blood. 2012. 120. (26). 5128–5133.</mixed-citation><mixed-citation xml:lang="en">Hirji I., Gupta S., Goren A., Chirovsky D.R., Moadel A.B., Olavarria E., Victor T.W., Davis C.C. Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient’s perspective // Health Qual. Life Outcomes. 2013. 11. (1). 167.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Barosi G., Mesa R., Finazzi G., Harrison C., Kiladjian J.J., Lengfelder E., McMullin M.F., Passa¬monti F., Vannucchi A.M., Besses C., Gisslinger H., Samuelsson J., Verstovsek S., Hoffman R., Pardanani A., Cervantes F., Tefferi A., Barbui T. Revised response criteria for polycythemia vera and essential thrombo¬cythemia: an ELN and IWG-MRT consensus project // Blood. 2013. 121. (23). 4778–4781.</mixed-citation><mixed-citation xml:lang="en">Höglund M., Sandin F., Hellström K., Björeman M., Björkholm M., Brune M., Dreimane A., Ekblom M., Lehmann S., Ljungman P., Malm C., Markevärn B., Myhr-Eriksson K., Ohm L., Olsson-Strömberg U., Själander A., Wadenvik H., Simonsson B., Stenke L., Richter J.Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry // Blood. 2013. 122. (7). 1284–1292.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Breccia M., Efficace F., Sica S., Abruzzese E., Cedrone M., Turri D., Gobbi M., Carella A.M., Gozzini A., Usala E., Cavazzini F., Danise P., Tiribelli M., Binotto G., Pregno P., Bocchia M., Gaidano G., Crugnola M., Bonifacio M., Avanzini P., Celesti F., Guella A., Martino B., Annunziata M., Luciano L., Stagno F., Vallisa D., Pungolino E., Iurlo A., Rambaldi A., Nardiello I., Orlandi E., Gambacorti-Passerini C., Alimena G. Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients // Leuk. Res. 2015. 39. (10). 1055–1059.</mixed-citation><mixed-citation xml:lang="en">Ionova T., Nikitina T., Lomaia E., Kuchma G., Machyulaytene E., Usacheva E., Shnaider T., Rodionova A., Kurbatova K. Quality of life and symptom profile in patients with Imatinib-resistant or intolerant chronic myeloid leukemia // Haematologica. 2012. 97. (1). 249.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Chen T.C., Chen L.C., Huang Y.B., Chang C.S. Imatinib adherence associated clinical outcomes of chronic myeloid leukaemia treatment in Taiwan // Int. J. Clin. Pharm. 2014. 36. (1). 172–181.</mixed-citation><mixed-citation xml:lang="en">Ionova T.I., Nikitina T.P., Lomaia E.G., Kuchma G.B., Machyulajtene E.R., Usachyova E.I., SHnejder T.V., Rodionova A.YU., Kurbatova K.A. Factors of life quality, area of symptoms and clinical effect from the second line dazatinib therapy in patients with resistant form of chronic myeloid leukemia or imatinib intolerance: results of the second-year monitoring survey. Onkogematologiya = Oncohematology. 2015. 10. (3). 18-27. [In Russian].</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Clark C.E., Taylor R.S., Shore A.C., Ukoumun¬ne O.C., Campbell J.L. Association of a difference in systolic blood pressure between arms with vascular disease and mortality: a systematic review and meta-analysis // Lancet. 2012. 379. (9819). 905–916.</mixed-citation><mixed-citation xml:lang="en">Kolesnikova I., Roitman E., Roumyantsev S., Ershova L., Roumiantseva J. Hemorheologic disturbances is venous thromboembolism risk factor in children with acute lymphoblastic leukemia (pilot study) // Thromb. Res. 2014. 133. (S3). 35-123.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Finazzi G., Barbui T. Evidence and expertise in the management of polycythemia vera and essential thrombocythemia // Leukemia. 2008. 22. (8). 1494–1502.</mixed-citation><mixed-citation xml:lang="en">Kwaan, H. C. Hyperviscosity in polycythemia vera and other red cell abnormalities // Semin. Thromb. Hemost. 2003. 29. (5). 451-458.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Flynn K.E., Atallah E. Quality of life and long term therapy in patients with chronic myeloid leuke¬mia // Curr. Hematol. Malig. Rep. 2016. 11. (2). 80–85.</mixed-citation><mixed-citation xml:lang="en">Landoli R., Gennaro L., Barbui T., Stefano V., Finazzi G., Marfisi R.M., Tognoni G., Marchioli R. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera // Blood. 2007. 109. (6). 2446-2452.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Guerin A., Chen L., Ionescu-Ittu R., Maryn¬chenko M., Nitulescu R., Hiscock R., Keir C., Wu E.Q. Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromoso¬me positive chronic myelogenous leukemia in chronic phase // Curr. Med. Res. Opin. 2014. 30. (11). 2317–2328.</mixed-citation><mixed-citation xml:lang="en">Lebedeva P.A. Endothelial dysfunction and arterial hypertension. Samara: Ofort, 2010. 192 p. [In Russian].</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance // Health Qual. Life Outcomes. 2006. 4. 79.</mixed-citation><mixed-citation xml:lang="en">Marchioli R., Finazzi G., Specchia G., Arianna Masciulli A., Mennitto M. R., Barbui T. The CYTO-PV: a large-scale trial testing the intensity of CYTOreductive therapy to prevent cardiovascular events in patients with polycythemia vera // Thrombosis. 2011. 2011. (1). 1-9.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Hamerschlak N., de Souza C., Cornacchio¬ni A.L., Pasquini R., Tabak D., Spector N., Steagall M. Quality of life of chronic myeloid leukemia patients in Brazil: ability to work as a key factor // Support. Care Cancer. 2014. 22. (8). 2113–2118.</mixed-citation><mixed-citation xml:lang="en">Mauro M.J., Davis C., Zyczynski T., Khoury H.J. The role of observational studies in optimizing the clinical management of chronic myeloid leukemia // Ther. Adv. Hematol. 2015. 6. (1). 3–14.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Hirji I., Gupta S., Goren A., Chirovsky D.R., Moadel A.B., Olavarria E., Victor T.W., Davis C.C. Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient’s perspective // Health Qual. Life Outcomes. 2013. 11. (1). 167.</mixed-citation><mixed-citation xml:lang="en">Melikayn A.L., Turkina A.G., Kovrigina A.M., Subortseva I.N.,Sudarikova A.B., Sokolova M.A., Zaritskiy A.Yu., Lomaia E.G., Shuvaev V.A., Gritsaev S.V., Martynkevich I.S., Afanasiev B.V., Morozova E.V., Baykov V.V., Golenkov A.K., Ivanova V.L., Kaplanov K.D., Pospelova T.I., Ageeva T.A., Shatokhin Yu.V., Savchenko V.G. Clinical recommendations for diagnosis and therapy of ph-negative myeloproliferative neoplasms (polycythemia vera, essential trombocythemia, primary myelofibrosis) (Edition 2016). Gematologiya i transfuziologiya = Gematology and Transfusiology. 2017. 62. (S1). 25-60. [In Russian].</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Höglund M., Sandin F., Hellström K., Björe¬man M., Björkholm M., Brune M., Dreimane A., Ekblom M., Lehmann S., Ljungman P., Malm C., Markevärn B., Myhr-Eriksson K., Ohm L., Olsson-Strömberg U., Själander A., Wadenvik H., Simonsson B., Stenke L., Richter J.Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry // Blood. 2013. 122. (7). 1284–1292.</mixed-citation><mixed-citation xml:lang="en">Mesa R.A, Niblack J., Wadleigh M., Verstovsek S., Camoriano J., Barnes S., Tan A.D., Atherton P.J.,  Sloan J.A., Tefferi A. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs) // Cancer. 2007. 109. (1). 68-76.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Ionova T., Nikitina T., Lomaia E., Kuchma G., Machyulaytene E., Usacheva E., Shnaider T., Rodio-nova A., Kurbatova K. Quality of life and symptom profile in patients with Imatinib-resistant or intolerant chronic myeloid leukemia // Haematologica. 2012. 97. (1). 249.</mixed-citation><mixed-citation xml:lang="en">Mesa R.A, Scherber R.M, Geyer H.L. Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors // Leuk. Lymphoma. 2015. 56. (7). 1989-1999.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Kolesnikova I., Roitman E., Roumyantsev S., Ershova L., Roumiantseva J. Hemorheologic distur-bances is venous thromboembolism risk factor in chil¬dren with acute lymphoblastic leukemia (pilot study) // Thromb. Res. 2014. 133. (S3). 35–123.</mixed-citation><mixed-citation xml:lang="en">Myasoedova N.A., Thostova EH.B., Belousov YU.B. Estimation of life quality of patients who has different cardiovascular diseases. Kachestvennaya klinicheskaya praktika = Good Clinical Practice. 2002. 4. (1). 53-57. [In Russian].</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Kwaan H.C. Hyperviscosity in polycythemia vera and other red cell abnormalities // Semin. Thromb. Hemost. 2003. 29. (5). 451–458.</mixed-citation><mixed-citation xml:lang="en">Noens L., van Lierde M.A., De Bock R, Verhoef G., Zachee P., Berneman Z., Martiat P., Mineur P., Van Eygen K., MacDonald K., De Geest S., Albrecht T., Abraham I. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study// Blood. 2009.113. (22). 5401–5411.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Landoli R., Gennaro L., Barbui T., Stefano V., Finazzi G., Marfisi R.M., Tognoni G., Marchioli R. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera // Blood. 2007. 109. (6). 2446–2452.</mixed-citation><mixed-citation xml:lang="en">Pye S.M., Cortes J., Ault P., Hatfield A., Kantarjian H., Pilot R., Rosti G., Apperley J.F.The effects of imatinib on pregnancy outcome// Blood. 2008. 111. (12). 5505–5508.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Marchioli R., Finazzi G., Specchia G., Arianna Masciulli A., Mennitto M.R., Barbui T. The CYTO-PV: a large-scale trial testing the intensity of CYTOreduc¬tive therapy to prevent cardiovascular events in patients with polycythemia vera // Thrombosis. 2011. 2011. (1). 1–9.</mixed-citation><mixed-citation xml:lang="en">Rybas A.V. Polycythemiya nera. Vestnik molodogo uchenogo = Journal of young scientist. 2016. 3. 19-25. [In Russian].</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Mauro M.J., Davis C., Zyczynski T., Khoury H.J. The role of observational studies in optimizing the clinical management of chronic myeloid leukemia // Ther. Adv. Hematol. 2015. 6. (1). 3–14.</mixed-citation><mixed-citation xml:lang="en">Saussele S., Krauss M.P., Hehlmann R., Lauseker M., Proetel U., Kalmanti L., Hanfstein B., Fabarius A., Kraemer D., Berdel W.E., Bentz M., Staib P., de Wit M., Wernli M., Zettl F., Hebart H.F., Hahn M., Heymanns J., Schmidt-Wolf I., Schmitz N., Eckart M.J., Gassmann W., Bartholomäus A., Pezzutto A., Leibundgut E.O., Heim D., Krause S.W., Burchert A., Hofmann W.K., Hasford J., Hochhaus A., Pfirrmann M., Müller M.C. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: Results of the randomized CML study IV // Blood. 2015.126. (1). 42–49.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Mesa R.A., Niblack J., Wadleigh M., Verstov¬sek S., Camoriano J., Barnes S., Tan A.D., Atherton P.J., Sloan J.A., Tefferi A. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs) // Cancer. 2007. 109. (1). 68–76.</mixed-citation><mixed-citation xml:lang="en">Scherber R., Dueck A.C. Johansson P., Barbui T., Barosi G., Vannucchi A.M., Passamonti F., Andreasson B., Ferarri M.L., Rambaldi A., Samuelsson J., Birgegard G., Tefferi A., Harrison C.N., Radia D., Mesa R.A. The myeloproliferative neoplasm symptom assessment form (MPN-SAF): international prospective validation and reliability trial in 402 patients // Blood. 2011. 118. (2). 401-408.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Mesa R.A., Scherber R.M., Geyer H.L. Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors // Leuk. Lymphoma. 2015. 56. (7). 1989–1999.</mixed-citation><mixed-citation xml:lang="en">Shihbabaeva D.I., Shuvaev V.A., Martynkevich I.S., Abdulkadyrov K.M., Zotova I.I., Udal'eva V.YU., Fominyh M.S., Zamotina T.B., Polushkina L.B. Their own experience of observation and treatment of patients with polycythemia vera. Vestnik gematologii = Hematology bulletin. 2015. 11. (4). 13-20. [In Russian].</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Noens L., van Lierde M.A., de Bock R., Ver¬hoef G., Zachee P., Berneman Z., Martiat P., Mineur P., van Eygen K., MacDonald K., de Geest S., Albrecht T., Abraham I. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study // Blood. 2009.113. (22). 5401–5411.</mixed-citation><mixed-citation xml:lang="en">Siegel F.P., Tauscher J., Petrides P.E. Aquagenic pruritus in polycythemia vera: Characteristics and influence on quality of life in 441 patients // Am. J. Hematol. 2013. 88. (8). 665-669.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Pye S.M., Cortes J., Ault P., Hatfield A., Kantarjian H., Pilot R., Rosti G., Apperley J.F.The effects of imatinib on pregnancy outcome // Blood. 2008. 111. (12). 5505–5508.</mixed-citation><mixed-citation xml:lang="en">Smith B.D. Imatinib for chronic myeloid leukemia: the impact of its effectiveness and long-term side effects // J. Natl. Cancer Inst. 2011. 103. (7). 527–529.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Saussele S., Krauss M.P., Hehlmann R., Lauseker M., Proetel U., Kalmanti L., Hanfstein B., Fabarius A., Kraemer D., Berdel W.E., Bentz M., Staib P., de Wit M., Wernli M., Zettl F., Hebart H.F., Hahn M., Heymanns J., Schmidt-Wolf I., Schmitz N., Eckart M.J., Gassmann W., Bartholomäus A., Pez¬zutto A., Leibundgut E.O., Heim D., Krause S.W., Burchert A., Hofmann W.K., Hasford J., Hochhaus A., Pfirrmann M., Müller M.C. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: Results of the randomized CML study IV // Blood. 2015. 126. (1). 42–49.</mixed-citation><mixed-citation xml:lang="en">Tefferi A. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management // Am. J. Hematol. 2012. 87. (3). 285-293.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Scherber R., Dueck A.C., Johansson P., Barbui T., Barosi G., Vannucchi A.M., Passamonti F., Andreasson B., Ferarri M.L., Rambaldi A., Samu¬elsson J., Birgegard G., Tefferi A., Harrison C.N., Radia D., Mesa R.A The myeloproliferative neoplasm symptom assessment form (MPN-SAF): international prospective validation and reliability trial in 402 patients // Blood. 2011. 118. (2). 401–408.</mixed-citation><mixed-citation xml:lang="en">Tyukina Yu.V., Lodygina T.I. Rate of vascular events in patients with polycythemia vera. Byulleten' Severnogo gosudarstvennogo medicinskogo universiteta = Bulletin of the Northern state medical university. 2011. (1). 141-142. [In Russian].</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Siegel F.P., Tauscher J., Petrides P.E. Aquagenic pruritus in polycythemia vera: Characteristics and influence on quality of life in 441 patients // Am. J. Hematol. 2013. 88. (8). 665–669.</mixed-citation><mixed-citation xml:lang="en">Unnikrishnan R., Veeraiah S., Mani S., Rajendranath R., Rajaraman S., Vidhubala Elangovan G.S., Radhakrishnan V., Ganesan T.S., Sagar T.G., Ganesan P. Comprehensive evaluation of adherence to therapy, its associations, and its implications in patients with chronic myeloid leukemia receiving imatinib // Clin. Lymphoma Myeloma Leuk. 2016. 16. (6). 366–371.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Smith B.D. Imatinib for chronic myeloid leu¬kemia: the impact of its effectiveness and long-term side effects // J. Natl. Cancer Inst. 2011. 103. (7). 527–529.</mixed-citation><mixed-citation xml:lang="en">Vayá A. Suescun M. Hemorheological parameters as independent predictors of venous thromboembolism // Clin. Hemorheol. Microcirc. 2013. 53. (1-2). 131-141.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Tefferi A. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management // Am. J. Hematol. 2012. 87. (3). 285–293.</mixed-citation><mixed-citation xml:lang="en">Venegoni P., Cyprus G. Polycythemia and the heart. A review // Tex. Heart Inst. J. 1994. 21. (1). 198-201.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Unnikrishnan R., Veeraiah S., Mani S., Rajend¬ranath R., Rajaraman S., Vidhubala Elangovan G.S., Radhakrishnan V., Ganesan T.S., Sagar T.G., Ganesan P. Comprehensive evaluation of adherence to therapy, its associations, and its implications in patients with chronic myeloid leukemia receiving imatinib // Clin. Lymphoma Myeloma Leuk. 2016. 16. (6). 366–371.</mixed-citation><mixed-citation xml:lang="en">Volkova M.A. Clinical oncohematology. Moscow: Meditsina, 2007. 1144 p. [In Russian].</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Vayá A., Suescun M. Hemorheological para¬meters as independent predictors of venous thrombo-embolism // Clin. Hemorheol. Microcirc. 2013. 53. (1-2). 131–141.</mixed-citation><mixed-citation xml:lang="en">Vorob'ev A.I., Al'-Radi L.S., Andreeva N.E. Rational pharmacotherapy of blood disorders. Moscow: Litterra, 2009. 688 p. [In Russian].</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Venegoni P., Cyprus G. Polycythemia and the heart. A review // Tex. Heart Inst. J. 1994. 21. (1). 198–201.</mixed-citation><mixed-citation xml:lang="en">Zav'yalova A. I. Policitemia vera and arterial hypertension or painless myocardial ischemia. Abstract of thesis….cand. med. sciences. Moscow, 2006. [In Russian].</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
